

Achieve Better Resolution for Large Biologics with


bioZen WidePore C4

- Optimal Wide Pore Distribution on a Core-Shell Particle
- Better Resolution for Intact mAbs and Subunit Analysis



bioZen" WidePore C4

Part of the bioZen Portfolio



Chemistries





Biocompatible Hardware

Easy Efficiency Gains When Using bioZen WidePore C4 Core-Shell Particle

- Improved Resolution, Sensitivity, and Speed with Core-Shell Technology
- Better Separation with Optimal Pore Size Distribution
- Enhanced Peak Shape Driven by Bioinert Hardware

Generating Next Level of Reliability Through Advanced Process Optimization

Intact and Subunit Applications Designed to Widen Your Expectations

A Team of Technical Bioseparation Experts to Help and Connect YOU

Ordering Information

Intact & Subunit Applications

Impurity profiling and characterization of intact biologic fragments is a challenging undertaking because of the need to identify very small differences between variants. bioZen™ WidePore C4 columns contain skillfully manufactured large pore core-shell particles that provide narrower, taller peaks in conjunction with higher resolution between the target HC/LC, Fc/Fab, or isoforms and are ideal for large biologics to optimize analysis.

Diverse Intact mAb Chromatographic Comparison using bioZen WidePore C4

Cetuximab	p.	8
Infliximab	p.	8
Infliximab Biosimilar	p.	8
Rituximab	p.	8

Method Optimization for WidePore C4

Flow Rate		p.	9
<u>Temperature</u>	<u> </u>	p.	10
Gradient		ם.	11

More Applications Available Online >>

www.phenomenex.com/bioZenWidePore



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Introducing

A New Solution for Your Intact mAbs and Subunit Analysis with bioZen™

With a single innovative product line, bioZen separation products provide enhanced characterization over an incredibly wide range of techniques.

3 Particle Platforms



Thermally Modified Fully Porous




Monosized Polymeric
Non-Porous



Core-Shell Technology

8 Particle Chemistries

Intact/Subunit



bioZen Intact XB-C8

Large pore core-shell particle for fast intact and subunit biologic entry. C8 provides highly useful moderate hydrophobic selectivity.



bioZen WidePore C4 2.6 µm

Core-shell particle with butyl stationary phase and optimal wide pore size distribution for better resolution of large biologics, including monoclonal antibodies and subunit analysis.

Size Exclusion (SEC)



bioZen SEC-2 1.8µm


Extremely inert, high density fully porous particle with high efficiency and low molecular weight (LMW) separation range of 1k-450 kDa.



bioZen SEC-3


Extremely inert, high density fully porous particle with high efficiency and high molecular weight (HMW) separation range of 10 k-700 kDa.

Peptide



bioZen Peptide PS-C18 1.6 µm and 3 µm


Excellent retention by combined positively charged surface ligand and C18 ligand.



bioZen Peptide XB-C18 1.7 µm and 2.6 µm

Overall retention of both acidic and basic peptides through C18 stationary phase with di-isobutyl side chains.


Glycan



bioZen Glycan 2.6µm

Provides optimal combination of high efficiency and selectivity for released glycans.

Ion-Exchange



bioZen WCX 6µm


Monosized particles grafted with linear polycarboxylate chains to envelop and separate proteins from acidic/basic variants

Advanced C4 Chemistry

bioZen[™] 2.6 µm WidePore C4 is an intact core-shell reversed phase column that provides good peak shape and selectivity for both intact monoclonal antibodies (mAbs) and subunit analyses. Its robust surface grafting and optimal particle and pore size morphology ensures high reproducibility for analytical methods.


bioZen WidePore C4 is designed for better resolution of large biologics using:

- Core-Shell Advantage for High Efficiency
- Optimal Pore Size for Better Separation
- Bioinert Hardware for Improved Peak Shape
- Robust Surface Chemistry for Improved Column Stability




Core-Shell Advantage

For an **increase in resolution**, along with faster and **more consistent results**, our scientists create a durable, homogeneous spherical porous shell **uniformly** grown on a solid silica core.




Controlled Wide Pore Technology




A wider pore LC column (~400Å) allows for better separation of large biologics and with a controlled manufacturing process, bioZen WidePore introduces a new solution for analyzing intact and subunit mAbs.

nside bioZen[™] BioTi™

Biocompatible Hardware






Generating the Next Level

Of Reliability Through Advanced Process Optimization


Over the past three years, our scientists and engineers with the help of customers and Danaher colleagues, have optimized our processes to provide products that deliver very high levels of performance and newly achievable levels of reliability and reproducibility. This new advanced series of products and process optimization is called PEAK.



Diverse mAb Comparison

with Chromatographic Performance Suitable for Intact MS Analysis

- High throughput and single method for multiple mAb analysis
- High temperature leads improved peak shape for all mAbs
- Formic acid mobile phase ensures sensitivity for intact mass by high resolution MS



	Retention Time	
Sample	(min)	Width @ 50 %
Rituximab	3.580	0.0233
Infliximab Biosimilar	3.606	0.0272
Cetuximab	3.696	0.0270
Infliximab	3.615	0.0222


Improved peak shape for intact mass applications by high resolution MS.

Temperature Effects on

Intact and Subunit Analysis

- Displays improved temperatures for Intact Influximab and Reduced NIST mAb at 70, 80, and 90°C
- 80 °C exhibits narrowest and most ideal peak shape for both the intact and subunit analysis

Intact Influximab



LC Conditions

Column: bioZen™ 2.6 µm WidePore C4

Dimension: 100 x 2.1 mm
Part No.: 00D-4786-AN
Mobile Phase: A: 0.1 % TFA in Water

B: 0.1 % TFA in Acetonitrile

Gradient: 20-55 % B in 6 minutes (Intact)

25-45 % B in 6 minutes (intact)

Flow Rate: 0.5 mL/min

Temperature: As Indicated


Detection: UV @ 280 nm (Intact)

UV @ 214 nm (Subunit)


Sample: Infliximab (1 mg/mL)

DTT-reduced NIST mAb (1 mg/mL)


Intact Detailed Overlay



HC/LC Subunit Analysis of NIST mAb



Heavy Chain Detailed Overlay



Ideal peak shape at 80 °C with high temperature stability using bioZen WidePore C4

Flow Rate Effects on Intact and Subunit Analysis

- Comparing 0.5, 0.6, 0.7, 0.8 mL/min flow rates for peak capacity of NIST mAb
- Faster flow rates help overcome slow diffusion rates and provides sharp, narrowing peaks
- Higher flow rates lead to higher throughput

LC Conditions

Column: bioZen™ 2.6 µm WidePore C4

Dimension: 100 x 2.1 mm Part No.: 00D-4786-AN Mobile Phase: A: 0.1 % TFA in Water


B: 0.1 % TFA in Acetonitrile Gradient: 25-45 % B in 6 minutes


Flow Rate: As indicated Injection Volume: 2 µL Temperature: 90 °C

> Detection: UV @ 280 nm (Intact) UV @ 214 nm (Subunit) Sample: NIST mAb (1 mg/mL)


DTT-reduced NIST mAb (1 mg/mL)

Intact NIST mAb Flow Rate






Subunit Analysis of NIST mAb



Detailed Overlay Comparison




A late eluting variant can be observed at 0.8 mL/min but not in 0.5 mL/min

Gradient Effects on


NIST mAb Subunit Analysis

- Comparing gradient effects of changing 20-55% B to 25-45% B
- Shallowing of gradient slope provides improved resolution and enable characterization of closely eluting impurities

Subunit Analysis of NIST mAB



Reduced Detailed Overlay



bioZen WidePore C4 displays an increase in resolution

LC Conditions

Column: bioZen™ 2.6 µm WidePore C4

Dimension: 100 x 2.1 mm
Part No.: 00D-4786-AN
Mobile Phase: A: 0.1 % TFA in Water

B: 0.1 % TFA in Acetonitrile

Gradient: As indicated
Flow Rate: 0.5 mL/min
Injection Volume: 2 µL
Temperature: 90 °C

Detection: UV @ 280 nm (Intact) UV @ 214 nm (Subunit)

Sample: DTT-reduced NIST mAb (1 mg/mL)

Interested in learning more about these applications?

Go to

www.phenomenex.com/bioZenWidePore to view these applications and more

A Full Team

Of Bioseparations Technical Experts

Trust our team of technical experts who are available for your questions and help to set up your method



Ordering Information

bioZen™ Products - Powered by Biocompatible Hardware

bioZen Columns (mm)								Biocompa	ntible Guard C	artridges
	50 x 2.1	100 x 2.1	150 x 2.1	50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	for 2.1 mm	for 4.6 mm	Holder
								/3pk	/10pk	ea
bioZen 2.6 µm Glycan	00B-4773-AN	00D-4773-AN	00F-4773-AN	_	_	_	_	AJ0-9800	_	AJ0-9000
bioZen 1.6 µm Peptide PS-C18	00B-4770-AN	00D-4770-AN	00F-4770-AN	_	_	_	_	AJ0-9803	_	AJ0-9000
bioZen 3 µm Peptide PS-C18	00B-4771-AN	_	00F-4771-AN	00B-4771-E0	_	00F-4771-E0	_	AJ0-7605	AJ0-7606	KJ0-4282
bioZen 1.7 µm Peptide XB-C18	00B-4774-AN	00D-4774-AN	00F-4774-AN	_	_	_	_	AJ0-9806	_	AJ0-9000
bioZen 2.6 µm Peptide XB-C18	00B-4768-AN	00D-4768-AN	00F-4768-AN	00B-4768-E0	_	00F-4768-E0	_	AJ0-9806	AJ0-9808	AJ0-9000
bioZen 2.6 µm WidePore C4	00B-4786-AN	00D-4786-AN	00F-4786-AN	00B-4786-E0	00D-4786-E0	00F-4786-E0	00G-4786-E0	AJ0-9809	AJ0-9811	AJ0-9000
bioZen 3.6 µm Intact XB-C8	00B-4766-AN	00D-4766-AN	00F-4766-AN	00B-4766-E0	_	00F-4766-E0	_	AJ0-9812	AJ0-9814	AJ0-9000

	50 x 2.1	100 x 2.1	150 x 2.1	250 x 2.1	50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	300 x 4.6	for 4.6 mm	Holder
										/3pk	ea
bioZen 1.8 µm SEC-2	00B-4769-AN	_	00F-4769-AN	_	_	_	00F-4769-E0	_	00H-4769-E0	AJ0-9850	AJ0-9000
bioZen 1.8 µm SEC-3	00B-4772-AN	_	00F-4772-AN	_	_	00D-4772-E0	00F-4772-E0	_	00H-4772-E0	AJ0-9851	AJ0-9000
										for 4.6 mm	Holder
										/10pk	ea
bioZen 6 µm WCX	00B-4777-AN	00D-4777-AN	00F-4777-AN	00G-4777-AN	00B-4777-E0	00D-4777-E0	00F-4777-E0	00G-4777-E0	_	AJ0-9400	KJ0-4282


Sample Preparation

bioZen Solid Phase Extraction	Format	Sorbent Mass	Part Number	Unit
bioZen N-Glycan Clean-Up	Microelution 96-Well Plate	5 mg/well	8M-S009-NGA	1/box



bioZen MagBeads Streptavidin Coated

Formats	Part No.	Concentration	Bead Size
25 mg (≈50 samples) 50 mg (≈100 samples) 500 mg (≈1000 samples)	KS0-9531 KS0-9532 KS0-9533	20 mg/mL	1.0 µm





Available to Chat 24/7

for Method Development and Optimization



Chat Now

www.phenomenex.com/ChatNow





Pore C4

Australi

Austria t: +43 (0)1-319-1301 anfrage@phenome

Belgium +32 (0)2 503 4015 (French +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

Denmark

t: +45 4824 8048 nordicinfo@phenomenex.com

Finland t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

India t: +91 (0)40-3012 2400 indiainfo@phenomenex.com

Ireland t: +353 (0)1 247 5405 eireinfo@phenomenex.com

Italy t: +39 051 6327511 italiainfo@phenomenex.com

Luxembourg +31 (0)30-2418700 nlinfo@phenomenex.com

Mexico t: 01-800-844-5226 tecnicomx@phenomenex.com

The Netherlands

+31 (0)30-2418700 nlinfo@phenomenex.com

New Zealand +64 (0)9-4780951

Poland

+48 (12) 881 0121 pl-info@phenomenex.com

Portugal t: +351 221 450 488 ptinfo@phenomenex.com

Singapore +65 800-852-3944 sainfo@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

Sweden t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan t: +886 (0) 0801-49-1246 twinfo@phenomenex.co

United Kingdom t: +44 (0)1625-501367 ukinfo@phenomenex.com

t: +1 (310) 212-0555 info@phenomenex.com

All other countries/ regions

Corporate Office USA t: +1 (310) 212-0555 info@phenomenex.com

Pphenomenex[®] ..breaking with tradition^s

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

Terms and Conditions Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks bioZen, BioTi, and BE-HAPPY are trademarks of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2020 Phenomenex, Inc. All rights reserved.